Biobanks Market Size, Share, and Growth Forecast 2026 - 2033

The global biobanks market is expected to be valued at US$ 92.3 billion in 2026 and is projected to reach US$ 154.6 billion by 2033, growing at a CAGR of 7.6% between 2026 and 2033.

Market growth is driven by the shift toward precision medicine, which depends on large, well-annotated collections of human biological samples linked to clinical and genomic data. Population programs such as UK Biobank, with 500,000 participants, and the National Institutes of Health (NIH) All of Us Research Program show how governments are scaling sample infrastructure. Rising cancer incidence and expanding cell and gene therapy pipelines are further supporting market growth.

Drivers - Expansion of Precision Medicine and Large-Scale Genomic Programs

Precision medicine has transformed biobanks from conventional sample storage facilities into critical research infrastructure. Large national and population-based genomic programs are generating sustained demand for biospecimen collection, cryogenic storage, automated sample handling, and data management services. UK Biobank released whole-genome sequencing data for all 500,000 participants in November 2023, creating one of the world's largest population-scale genomic datasets. In the U.S., the NIH All of Us Research Program published findings in Nature in February 2024 based on nearly 245,000 whole genomes, as part of its goal to enroll at least 1 million participants.

Similar large-scale programs, including FinnGen, which covers around 500,000 Finnish participants, and the China Kadoorie Biobank, which includes more than 512,000 adults, are expanding the need for long-term biospecimen management. These programs require storage and management of millions of samples and associated datasets, supporting recurring demand for biobank equipment, automation, and specialized services.

Rising Cancer Burden and Growth in Biomarker-Driven Drug Development

The increasing burden of cancer and other chronic diseases is strengthening demand for high-quality human tissues, blood samples, and other biospecimens. The International Agency for Research on Cancer (IARC) estimated around 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022 and projects global cancer cases to exceed 35 million annually by 2050. Oncology research increasingly depends on well-characterized tumor tissues, matched normal samples, and blood derivatives for biomarker discovery, target validation, and patient selection.

Pharmaceutical companies are also expanding biomarker-driven clinical development, increasing the need for well-annotated samples linked with clinical and genomic information. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) continue to support the use of companion diagnostics for selecting patients for targeted therapies. Consequently, pharmaceutical and biotechnology companies are forming partnerships with hospital, academic, and commercial biobanks to obtain specialized specimens, supporting demand for biospecimen procurement, processing, characterization, and long-term storage services.

Restraints - Data Privacy, Consent and Regulatory Complexity

Data privacy, informed consent, and regulatory requirements remain major challenges for the biobanking industry. In Europe, the General Data Protection Regulation (GDPR) classifies genetic and health information as special-category personal data and provides for fines of up to €20 million or 4% of global annual turnover, whichever is higher. These requirements increase the compliance burden for biobanks handling identifiable or potentially re-identifiable genomic and clinical information.

Regulatory complexity is also significant in cross-border research. China's Regulation on the Administration of Human Genetic Resources, which came into force in 2019, establishes requirements for the collection, preservation, utilization, and international transfer of human genetic resources. Differences in informed-consent requirements, including specific and broad consent models, can further complicate secondary use of samples. Biobanks therefore need robust governance, data security, consent management, and documentation systems. These requirements can increase operational costs, extend research timelines, and restrict the ability to share or commercially utilize certain biospecimen collections.

Opportunities - Automation, Digital Biobanking and Multi-Omics Partnerships

Automation, digitalization and advanced data integration are creating opportunities for biobanks to expand beyond traditional sample storage services. Automated sample-management systems from companies such as Hamilton Company and Thermo Fisher Scientific can reduce manual handling, improve sample tracking and support large-scale storage operations. Laboratory information management systems, digital sample catalogs and AI-enabled search tools can also help researchers identify and request relevant specimens more efficiently. These technologies allow biobanks to increase throughput while improving traceability and sample integrity.

Multi-omics research is creating additional opportunities for biobanks with large, well-characterized collections. In January 2025, UK Biobank launched the Pharma Proteomics Project with 14 pharmaceutical companies to measure around 5,400 proteins in 600,000 samples. Such initiatives demonstrate growing pharmaceutical interest in extracting additional biological insights from existing collections. Biobanks that combine high-quality biospecimens with linked clinical, genomic, proteomic and other molecular data can create higher-value offerings through research partnerships, consortium access, data-sharing arrangements and customized analysis services.

Offering Insights

Products account for around 62% of the biobanks market in 2026, making them the leading offering segment. Biobanks require temperature and humidity control systems, cryogenic storage equipment, thawing systems, alarms, and monitoring solutions to maintain sample quality. Large-scale facilities such as UK Biobank manage millions of sample aliquots and require advanced ultra-low-temperature and liquid nitrogen storage systems for long-term preservation. Replacement of aging equipment, demand for energy-efficient systems, and increasing adoption of remote monitoring technologies continue to support product demand.

Services are projected to record the fastest CAGR between 2026 and 2033. Pharmaceutical companies and research institutions are increasingly outsourcing sample processing, storage, transportation, data management, and other biobanking activities to specialized providers. This trend allows organizations to reduce infrastructure requirements while accessing specialized expertise and scalable storage capacity.

Sample Type Insights

Human tissues represent the leading segment, accounting for around 37% of the biobanks market share in 2026. Tumor biopsies, surgical specimens, and matched normal tissues are widely used in oncology research, pathology, biomarker discovery, and companion diagnostic development. The IARC reported around 20 million new cancer cases globally in 2022, supporting continued demand for well-characterized tissue collections. Initiatives such as the NCI Cooperative Human Tissue Network have also supported the availability of human tissues for biomedical research.

Stem cells are projected to record the fastest CAGR between 2026 and 2033, supported by growing cell and gene therapy research, induced pluripotent stem cell (iPSC) applications, and increasing demand for long-term stem cell preservation. Expansion of private cord blood banking and regenerative medicine research further supports the development of specialized stem cell storage capabilities.

Application Insights

Drug discovery & clinical research represent the dominant application, holding about 41% share of the market in 2026. Pharmaceutical and biotechnology companies use biobank samples for target identification, biomarker validation, patient stratification, and retrospective research. Clinical studies also generate large volumes of biospecimens that require controlled storage and long-term management. Central biorepositories are increasingly used to manage these samples under standardized conditions and in accordance with regulatory requirements.

Therapeutics is projected to record the fastest CAGR through 2033, supported by the development of cell and gene therapies, CAR-T treatments, and regenerative medicine. These therapies require specialized storage of starting materials, biological components, and cryopreserved products. Increasing development of advanced therapies is therefore creating demand for biobanks capable of providing controlled, traceable, and GMP-compatible storage environments.

Biobank Type / Ownership Insights

Academic and research institute biobanks accounted for 34% of the market share in 2026. Universities, teaching hospitals, and research organizations operate numerous disease-specific, population-based, and clinical biobanks. These facilities benefit from public research funding and direct access to patient populations. BBMRI-ERIC connects biobanks and biomolecular resources across Europe, supporting collaborative research and access to diverse biospecimen collections.

Private/commercial biobanks are projected to record the fastest CAGR between 2026 and 2033. Pharmaceutical companies are increasingly outsourcing sample sourcing, processing, and storage to specialized providers. Growth in cord blood banking and increasing demand for scalable storage solutions among cell and gene therapy developers are also creating opportunities. Commercial providers can support these requirements through specialized facilities, digital sample management, and flexible storage services.

North America Biobanks Market Trends and Insights

North America represents a significant market, supported by substantial pharmaceutical R&D investments, advanced healthcare infrastructure, leading academic medical centers, and a strong presence of biobanking technology suppliers. Large federally funded genomic initiatives and expanding clinical research programs are increasing demand for efficient sample collection, processing, storage, and management solutions.

The region is also witnessing greater adoption of commercial biorepository services, particularly among pharmaceutical and biotechnology companies seeking scalable sample-management capabilities. Growing cell and gene therapy pipelines are driving demand for specialized storage systems, while automation, remote monitoring, digital tracking, and advanced laboratory workflows are improving operational efficiency and supporting the modernization of biobank facilities.

U.S. Biobanks Market Size

The U.S. is projected to account for 88% of the North American biobanks market revenue in 2026, reflecting its extensive healthcare infrastructure, advanced laboratory technologies, substantial pharmaceutical R&D expenditure, and broad network of academic medical centers. Large-scale initiatives, including the NIH All of Us Research Program, are expected to continue supporting demand for sophisticated sample collection, storage, processing, and data-management solutions.

A strong biotechnology ecosystem, expanding cell and gene therapy pipelines, commercial biorepository services, and increasing adoption of automated storage systems will reinforce market development. Federal research funding, advanced clinical research capabilities, and growing pharmaceutical collaborations are expected to encourage continued investment in biobanking infrastructure and specialized sample-management technologies.

Europe Biobanks Market Trends and Insights

Europe is projected to lead the global biobanks market by holding around 38% share in 2026. Its strong position is supported by established population cohorts, advanced healthcare and research infrastructure, coordinated biobanking networks, and active pharmaceutical research. BBMRI-ERIC further strengthens collaboration and promotes standardized biobanking practices across European countries.

Growing adoption of multi-omics research, precision medicine, and integrated health-data platforms is expected to support continued market development. Harmonized quality standards, cross-border research initiatives, expanding genomic databases, and increasing investments in automated sample management and advanced storage technologies are further improving biobank capabilities and encouraging greater utilization across academic, clinical, and pharmaceutical research applications.

Germany Biobanks Market Size

Germany is projected to hold about 25% share of the European market in 2026, reflecting its advanced healthcare infrastructure, extensive research network, and strong pharmaceutical and medical technology industries. The German Biobank Alliance and NAKO Gesundheitsstudie provide established platforms for standardized sample collection, long-term storage, clinical research, and population-based biomedical investigations, supporting sustained demand across institutions.

Government-backed research programs, sophisticated laboratory automation, and increasing adoption of genomic and multi-omics technologies are expected to reinforce Germany's position. Strong university hospitals, biotechnology companies, and pharmaceutical organizations are further expected to encourage investments in high-quality biobanking equipment, informatics systems, sample-management solutions, and specialized storage infrastructure.

U.K. Biobanks Market Size

The U.K. is projected to account for 23% of the European market share in 2026, supported by sophisticated healthcare infrastructure, globally recognized research institutions, and extensive population-based datasets. UK Biobank, Genomics England, and Our Future Health provide substantial biological resources for genomic, epidemiological, and precision-medicine research, strengthening demand for advanced repository capabilities.

Strong government research funding, pharmaceutical partnerships, and established regulatory frameworks are expected to encourage continued technology adoption. Investments in automated sample handling, data integration, proteomics, and personalized medicine are expected to expand biobanking applications across academic institutions, healthcare organizations, pharmaceutical companies, and biotechnology research programs throughout the country.

Asia Pacific Biobanks Market Trends and Insights

Asia Pacific is expected to remain the fastest-growing market, supported by increasing healthcare investments, expanding clinical trial activity, and the development of national genomic initiatives. Rising adoption of precision medicine and personalized healthcare is encouraging governments, hospitals, pharmaceutical companies, and research institutions to establish advanced biobanking infrastructure and strengthen biological sample collection and storage capabilities.

China is emerging as a major regional hub, supported by the China Kadoorie Biobank, expanding hospital-based repositories, and substantial biomedical research activity. Stem cell banking, precision oncology, genomic research, and advanced sample-processing technologies are gaining traction. Meanwhile, human genetic resource regulations continue to influence international research collaboration and data-sharing practices.

India Biobanks Market Size

India is projected to hold about 14% share of the Asia Pacific market in 2026, supported by expanding healthcare infrastructure, increasing clinical research activity, and growing investment in genomics and precision medicine. GenomeIndia's population-scale sequencing initiative, alongside ICMR-supported research frameworks, is strengthening national capabilities in biological sample collection, genomic analysis, and biomedical research applications.

Growing biotechnology activity, private cord blood banking, hospital-based repositories, and increasing adoption of advanced laboratory technologies are expected to support future expansion. Government initiatives, improving research infrastructure, and rising demand for personalized healthcare are expected to encourage pharmaceutical companies, academic institutions, hospitals, and biotechnology organizations to increase investments in biobanking facilities and associated technologies.

Japan Biobanks Market Size

Japan is projected to account for 32% of the Asia Pacific biobanks market share in 2026, supported by advanced healthcare infrastructure, sophisticated biomedical research capabilities, and strong adoption of genomic and regenerative medicine technologies. BioBank Japan, the Tohoku Medical Megabank, and CiRA's iPSC initiatives provide established platforms for large-scale sample collection and research applications.

Supportive regenerative medicine policies, substantial public research investment, and advanced laboratory automation are expected to encourage continued development. Strong pharmaceutical, biotechnology, and academic participation is expected to increase demand for specialized storage systems, sample-processing technologies, genomic data management, and high-quality biorepository services, particularly for precision medicine and cell-based research programs.

The global biobanks market is moderately fragmented. Equipment and consumable leaders such as Thermo Fisher Scientific, Merck KGaA, Danaher, BD, Qiagen, Hamilton Company and Tecan compete alongside service providers including Charles River Laboratories, Lonza and specialized biorepositories, while cord blood banks and academic biobanks form a long regional tail. Leaders differentiate through automated, high-density storage, integrated sample management software, validated cold chain solutions and global service networks.

R&D focuses on energy-efficient freezers, AI-enabled monitoring and multi-omics sample analysis. Emerging business models include biobanking-as-a-service, consortium-funded data access, and end-to-end GMP storage for cell and gene therapy developers.

Key Industry Developments

• In October 2026, the Department of Laboratory Medicine and Pathology (DLMP) at Hamad Medical Corporation (HMC) announced the launch of the Human Tissue Biobank in collaboration with the Qatar Precision Health Institute (QPHI).
• In July 2025, Dr. Jitendra Singh, Union Minister of State (Independent Charge) for Science & Technology and Vice President of CSIR, inaugurated the state-of-the-art Phenome India “National Biobank” at CSIR-IGIB in New Delhi.